Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could skipping a common additive make numbing shots safer and just as effective?

NCT ID NCT07342010

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether leaving out bicarbonate from the numbing medicine (lidocaine with adrenaline) affects how well people recover the day after hand or foot surgery. About 150 adults having common procedures like carpal tunnel release or bunion surgery will be randomly assigned to get the numbing mix with or without bicarbonate. The goal is to see if the simpler, ready-to-use solution is just as good for recovery and might be safer and easier to prepare.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years) eligible for ambulatory surgery under WALANT for Hand surgery (including carpal tunnel release, trigger finger release, or Dupuytren's disease surgery) and foot surgery (including hallux valgus or hallux rigidus.) * Provision of free and informed consent. * Signed informed consent form. * Affiliation with or beneficiary of a health insurance system Exclusion Criteria: * Ischemic vascular disorders, including severe Raynaud's disease, Buerger's disease, or diabetic microangiopathy. * Scleroderma. * Known allergy to lidocaine or potential cross-reactivity with other amide-type local anesthetics. * Severe hepatic impairment. * Acute porphyria. * Intravascular administration of local anesthesia. * Local anesthetic infiltration at the level of the extremities. * Coronary artery disease. * Ventricular arrhythmias. * Severe arterial hypertension. * Obstructive cardiomyopathy. * Hyperthyroidism. * Hypovolemia. * Participation in an interventional clinical research study classified as category 1 (RIPH category 1). * Ongoing exclusion period related to participation in another clinical study. * Legal protection status (guardianship, trusteeship, or judicial protection). * Inability to provide informed consent. * Inability to receive or understand adequate study information. * Pregnancy, labor, or breastfeeding. Women of childbearing potential will undergo a urine pregnancy test prior to inclusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anesthesia, local are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yann GRICOURT

    Nîmes, Gard, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.